A flurogold labeled-retina flatmount (front) representing surviving retinal ganglion cells, and the chemical structure of trimetazidine (background). In Clinical Science volume 131, issue 18, Wan et al. report that trimetazidine protects retinal ganglion cells against acute glaucoma via the Nrf2/Ho-1 pathway and propose it as a novel therapeutic agent; for details, see pages 2363-2375.